Slingshot Biosciences has announced its further expansion into the United Kingdom (UK) and European Union (EU) markets. This investment provides the product innovators in the region with broader access and faster adoption of Slingshot's reproducible, premium-quality biomarker controls in their cell-based assay development programmes. The company's aggressive growth continues, driven by the broad adoption of its cell-mimic technology by hundreds of pharmaceutical companies, biotechnology firms, Contract Research Organisations (CROs), clinical diagnostics laboratories and academic medical centres worldwide.

Speaking in this regard, Glenn Bilawsky, Chief Executive Officer, Slingshot Biosciences, said, “The United Kingdom and European Union represent one of the world's most dynamic and innovative life sciences markets. These regions are home to top-tier research institutions, leading cell therapy companies and global pharmaceutical firms that share our dedication to advancing scientific rigour and reproducibility. We're excited about the rapid adoption of our technology in these markets and are expanding our commitment to researchers and manufacturers in their mission to develop life-saving therapies faster and more reliably."

Slingshot Biosciences' proprietary platform delivers precision-engineered synthetic cell mimics that eliminate the variability, fragility and operational inefficiency inherent in traditional biological controls. Lot-to-lot consistency achieves coefficients of variation as low as 0.1 percent. Researchers have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies. The company's synthetic cell-mimic controls enable researchers to achieve reproducible results across multiple sites and instruments, a critical requirement for clinical trials, cell therapy manufacturing, and rapid and successful regulatory submissions.